Document Detail


Oral contraceptive formulation and risk of breast cancer.
MedLine Citation:
PMID:  22067757     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: While evidence on the association between oral contraceptive (OC) use and breast cancer generally suggests little or no increased risk, the question of whether breast cancer risk varies by OC formulation remains controversial. Few studies have examined this issue because large samples and extensive OC histories are required.
STUDY DESIGN: We used data from a multicenter, population-based, case-control investigation. Women aged 35-64 years were interviewed. To explore the association between OC formulation and breast cancer risk, we used conditional logistic regression to derive adjusted odds ratios, and we used likelihood ratio tests for heterogeneity to assess whether breast cancer risk varied by OC formulation. Key OC exposure variables were ever use, current or former use, duration of use and time since last use. To strengthen inferences about specific formulations, we restricted most analyses to the 2282 women with breast cancer and the 2424 women without breast cancer who reported no OC use or exclusive use of one OC.
RESULTS: Thirty-eight formulations were reported by the 2674 women who used one OC; most OC formulations were used by only a few women. We conducted multivariable analyses on the 10 formulations that were each used by at least 50 women and conducted supplemental analyses on selected formulations of interest based on recent research. Breast cancer risk did not vary significantly by OC formulation, and no formulation was associated with a significantly increased breast cancer risk.
CONCLUSIONS: These results add to the small body of literature on the relationship between OC formulation and breast cancer. Our data are reassuring in that, among women 35-64 years of age, we found no evidence that specific OC formulations increase breast cancer risk.
Authors:
Polly A Marchbanks; Kathryn M Curtis; Michele G Mandel; Hoyt G Wilson; Gary Jeng; Suzanne G Folger; Jill A McDonald; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Phyllis A Wingo; Michael S Simon; Sandra A Norman; Brian L Strom; Giske Ursin; Linda K Weiss; Ronald T Burkman; Robert Spirtas
Related Documents :
21672237 - The prognostic significance of tumour cell detection in the peripheral blood versus the...
23152127 - Ornithine decarboxylase and glutamate decarboxylase 65 as prognostic markers of gallbla...
21709817 - Clinical epidemiology and pharmacology of cyp2d6 inhibition related to breast cancer ou...
21616717 - Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma.
12415427 - Cytochrome p450 cyp1b1 and catechol o-methyltransferase (comt) genetic polymorphisms an...
11720027 - Distribution of epidermal growth factor receptor (egfr) in normal and acute peptic-inju...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.     Date:  2011-09-28
Journal Detail:
Title:  Contraception     Volume:  85     ISSN:  1879-0518     ISO Abbreviation:  Contraception     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-16     Completed Date:  2012-07-16     Revised Date:  2013-10-17    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  342-50     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Affiliation:
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pam2@cdc.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Breast Neoplasms / chemically induced*
Case-Control Studies
Contraceptives, Oral / adverse effects*
Contraceptives, Oral, Hormonal / adverse effects*
Female
Humans
Interviews as Topic
Middle Aged
Questionnaires
Risk
Grant Support
ID/Acronym/Agency:
N01 CN065064/CN/NCI NIH HHS; N01 HD023166/HD/NICHD NIH HHS; N01 HD033168/HD/NICHD NIH HHS; N01 HD033174/HD/NICHD NIH HHS; N01 HD033175/HD/NICHD NIH HHS; N01 HD033176/HD/NICHD NIH HHS; N01 PC067006-009/PC/NCI NIH HHS; N01 PC067010/PC/NCI NIH HHS; N01-CN-0532/CN/NCI NIH HHS; N01-CN-65064/CN/NCI NIH HHS; N01-HD-2-3166/HD/NICHD NIH HHS; N01-HD-3-3168/HD/NICHD NIH HHS; N01-HD-3-3174/HD/NICHD NIH HHS; N01-HD-3-3175/HD/NICHD NIH HHS; N01-HD-3-3176/HD/NICHD NIH HHS; N01-PC-67006/PC/NCI NIH HHS; N01-PC-67010/PC/NCI NIH HHS; P30 CA015704/CA/NCI NIH HHS; Y01 HD007022/HD/NICHD NIH HHS; Y01-HD-7022/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Contraceptives, Oral; 0/Contraceptives, Oral, Hormonal
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of significant factors affecting acceptability of home administration of misoprostol for ...
Next Document:  A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding w...